Merck's Keytruda: A lifesaving drug, a global divide

Merck's Keytruda generated $31.7 billion in sales in 2025, but the investigation highlights a global access problem driven by pricing, reimbursement, patents and litigation. The drug's list price ranges from about $850 per vial in Indonesia to over $6,000 in the US, while annual treatment costs can reach roughly $208,000 in the US and $65,000-$116,000 in some lower-income markets. Reporters found 1,212 patent applications across 53 jurisdictions and at least 632 crowdfunding cases in 51 countries, underscoring a widening divide between commercial success and patient access.

Analysis

The market setup is not really about one drug; it is about whether the oncology value chain can keep monetizing incremental labeling, sequencing, and regimen complexity before policy backlash hardens. The biggest second-order beneficiary is the broader immuno-oncology ecosystem: every month of delayed generic/biologic competition preserves pricing power not just for the incumbent, but for adjacent checkpoint and combination therapies that can be positioned as “standard of care” extensions. That said, the more pricing scrutiny rises, the more payers will attack duration, dosing intensity, and line-of-therapy creep rather than headline access, which shifts the fight from patent law to utilization management.

The risk is asymmetric and time-framed in layers. Near term, this reads as noise for the stock because the franchise remains huge and cash generative; over 12-36 months, the overhang is policy + litigation + reimbursement compression, especially outside the US where governments can coordinate harder on reference pricing. The most underappreciated catalyst is not a patent cliff in 2028, but evidence that lower-dose or weight-based protocols preserve efficacy: if that idea generalizes, it cuts unit growth at the margin without waiting for biosimilars, and it becomes a payer-friendly wedge to force step-down pricing.

Contrarian view: the consensus may be overstating the durability of global pricing power but underestimating the optionality from pipeline reinvestment and capital returns. A company this concentrated can absorb moderate gross margin erosion if management is willing to trade some future revenue for buybacks and late-stage assets; the market may be too focused on headline sales and not enough on normalized free cash flow per share. The real loser is not just the incumbent, but smaller oncology innovators whose economics depend on a high-water-mark pricing regime—if the standard of care gets repriced, their launch assumptions compress immediately.

Key Decisions for Investors

• Short-dated put spread on MRK into any policy headline over the next 1-3 months; structure for limited premium outlay because the stock likely stays range-bound absent a US reimbursement event.
• Pair trade: long broader diversified pharma basket (PFE/BMY/ABBV proxy) vs short MRK over 6-12 months, betting the market rewards lower concentration risk and less patent-fortress exposure.
• Buy downside protection on oncology services/benefits managers with heavy exposure to high-cost checkpoint spend over 6-9 months; payer pushback could improve their negotiating leverage and margins.
• If MRK sells off 8-10% on access/repricing rhetoric without evidence of US formulary deterioration, fade the move via call spreads for a 3-6 month reversion trade; franchise cash flow remains too strong for a structural break on headlines alone.
• Watch for regulatory adoption of weight-based dosing in major ex-US markets; if that accelerates, consider reducing long-duration exposure to high-priced oncology names and shifting toward volume-based suppliers with lower pricing elasticity.